Which has preferable valuation & earnings, OLMA or AMLX?

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.12 N/A Amylyx Pharmaceuticals N/A N/A -$144.74M -$1.43 N/A

Is OLMA or AMLX more profitable?

Olema Pharmaceuticals' return on equity of -48.26% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -48.26% -43.04% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media favor OLMA or AMLX?

In the previous week, Olema Pharmaceuticals had 4 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat Olema Pharmaceuticals' score of 1.07 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RCUS or OLMA?

In the previous week, Olema Pharmaceuticals had 6 more articles in the media than Arcus Biosciences. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 4 mentions for Arcus Biosciences. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Arcus Biosciences' score of 1.05 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, DYN or OLMA?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.12 N/A

Is DYN or OLMA more profitable?

Olema Pharmaceuticals' return on equity of -48.26% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Olema Pharmaceuticals N/A -48.26% -43.04%

Does the media refer more to DYN or OLMA?

In the previous week, Dyne Therapeutics had 25 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 35 mentions for Dyne Therapeutics and 10 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Dyne Therapeutics' score of 0.31 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Olema Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OLMA or GRAL?

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than GRAIL. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 9 mentions for GRAIL. Olema Pharmaceuticals' average media sentiment score of 1.07 beat GRAIL's score of 0.96 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNLI or OLMA more profitable?

Olema Pharmaceuticals' return on equity of -48.26% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -55.27% -44.24% Olema Pharmaceuticals N/A -48.26% -43.04%

Does the media favor DNLI or OLMA?

In the previous week, Olema Pharmaceuticals had 8 more articles in the media than Denali Therapeutics. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Olema Pharmaceuticals' score of 1.07 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Olema Pharmaceuticals (OLMA) Competitors

$10.22 -0.47 (-4.40%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.82 -1.40 (-13.69%)

As of 09/11/2026 07:59 PM Eastern

Compare

OLMA vs. AMLX, RCUS, DYN, GRAL, and DNLI

Should you buy Olema Pharmaceuticals stock or one of its competitors? Olema Pharmaceuticals's main competitors and comparable companies include Amylyx Pharmaceuticals (AMLX), Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), GRAIL (GRAL), and Denali Therapeutics (DNLI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Olema Pharmaceuticals compare to Amylyx Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Olema Pharmaceuticals currently has a consensus price target of $42.40, suggesting a potential upside of 314.87%. Amylyx Pharmaceuticals has a consensus price target of $36.50, suggesting a potential upside of 15.43%. Given Olema Pharmaceuticals' higher probable upside, equities research analysts plainly believe Olema Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Olema Pharmaceuticals' return on equity of -48.26% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
Amylyx Pharmaceuticals	N/A	N/A	-$144.74M	-$1.43	N/A

In the previous week, Olema Pharmaceuticals had 4 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 6 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.50 beat Olema Pharmaceuticals' score of 1.07 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.13, suggesting that its share price is 113% less volatile than the broader market.

Summary

Olema Pharmaceuticals beats Amylyx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 7.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Olema Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Olema Pharmaceuticals' return on equity of -48.26% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-393.16%	-89.54%	-45.61%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

Olema Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.69	-$353M	-$3.90	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

In the previous week, Olema Pharmaceuticals had 6 more articles in the media than Arcus Biosciences. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 4 mentions for Arcus Biosciences. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Arcus Biosciences' score of 1.05 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcus Biosciences currently has a consensus target price of $38.30, suggesting a potential upside of 55.54%. Olema Pharmaceuticals has a consensus target price of $42.40, suggesting a potential upside of 314.87%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Arcus Biosciences has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market.

Summary

Olema Pharmaceuticals beats Arcus Biosciences on 13 of the 15 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Olema Pharmaceuticals' return on equity of -48.26% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

Dyne Therapeutics presently has a consensus price target of $32.17, suggesting a potential upside of 76.64%. Olema Pharmaceuticals has a consensus price target of $42.40, suggesting a potential upside of 314.87%. Given Olema Pharmaceuticals' higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Dyne Therapeutics had 25 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 35 mentions for Dyne Therapeutics and 10 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Dyne Therapeutics' score of 0.31 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

Dyne Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market.

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Olema Pharmaceuticals beats Dyne Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to GRAIL?

Olema Pharmaceuticals (NASDAQ:OLMA) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Olema Pharmaceuticals has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.25, indicating that its stock price is 225% more volatile than the broader market.

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than GRAIL. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 9 mentions for GRAIL. Olema Pharmaceuticals' average media sentiment score of 1.07 beat GRAIL's score of 0.96 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 12.6% of Olema Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of GRAIL shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Olema Pharmaceuticals currently has a consensus price target of $42.40, indicating a potential upside of 314.87%. GRAIL has a consensus price target of $71.11, indicating a potential downside of 6.72%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Olema Pharmaceuticals is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45

Olema Pharmaceuticals has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
GRAIL	$165.26M	20.60	-$408.35M	-$9.75	N/A

Olema Pharmaceuticals has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
GRAIL	-236.95%	-15.88%	-14.02%

Summary

Olema Pharmaceuticals beats GRAIL on 11 of the 16 factors compared between the two stocks.

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Olema Pharmaceuticals (NASDAQ:OLMA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Denali Therapeutics currently has a consensus target price of $35.85, indicating a potential upside of 69.97%. Olema Pharmaceuticals has a consensus target price of $42.40, indicating a potential upside of 314.87%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 9.7% of Denali Therapeutics shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Olema Pharmaceuticals had 8 more articles in the media than Denali Therapeutics. MarketBeat recorded 10 mentions for Olema Pharmaceuticals and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.46 beat Olema Pharmaceuticals' score of 1.07 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals' return on equity of -48.26% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-55.27%	-44.24%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

Olema Pharmaceuticals has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.20	-$512.54M	-$2.84	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

Denali Therapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market.

Summary

Olema Pharmaceuticals beats Denali Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Olema Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OLMA vs. The Competition

Export

Metric	Olema Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$935.35M	$3.85B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-4.82	14.18	274.10	25.29
Price / Sales	N/A	1,477.55	655.45	98.96
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	1.74	15.12	10.33	6.20
Net Income	-$162.45M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-4.93%	-4.35%	-3.33%	-2.35%
1 Month Performance	-2.11%	-0.03%	-0.41%	-2.77%
1 Year Performance	31.53%	40.63%	19.22%	7.63%

Olema Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OLMA Olema Pharmaceuticals	2.6948 of 5 stars	$10.22 -4.4%	$42.40 +314.9%	+27.8%	$935.35M	N/A	N/A	70	News Coverage Positive News
AMLX Amylyx Pharmaceuticals	3.9495 of 5 stars	$34.10 +0.0%	$36.50 +7.0%	+167.1%	$3.80B	$87.37M	N/A	200	Positive News
RCUS Arcus Biosciences	3.4239 of 5 stars	$29.39 -0.9%	$38.30 +30.3%	+114.0%	$3.74B	$247M	N/A	500	Positive News Analyst Forecast
DYN Dyne Therapeutics	3.1055 of 5 stars	$19.78 -18.5%	$34.42 +74.0%	+38.2%	$3.69B	N/A	N/A	100	Analyst Forecast Insider Trade Options Volume High Trading Volume
GRAL GRAIL	0.6883 of 5 stars	$80.34 0.0%	$67.78 -15.6%	+97.2%	$3.59B	$147.17M	N/A	1,360	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OLMA) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. AMLX, RCUS, DYN, GRAL, and DNLI

How does Olema Pharmaceuticals compare to Amylyx Pharmaceuticals?

Summary

How does Olema Pharmaceuticals compare to Arcus Biosciences?

Summary

How does Olema Pharmaceuticals compare to Dyne Therapeutics?

Summary

How does Olema Pharmaceuticals compare to GRAIL?

Summary

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Olema Pharmaceuticals (OLMA) Competitors

OLMA vs. AMLX, RCUS, DYN, GRAL, and DNLI

How does Olema Pharmaceuticals compare to Amylyx Pharmaceuticals?

Do insiders and institutionals have more ownership in OLMA or AMLX?

Do analysts rate OLMA or AMLX?

Is OLMA or AMLX more profitable?

Which has preferable valuation & earnings, OLMA or AMLX?

Does the media favor OLMA or AMLX?

Which has more risk & volatility, OLMA or AMLX?

Summary

How does Olema Pharmaceuticals compare to Arcus Biosciences?

Do institutionals & insiders have more ownership in RCUS or OLMA?

Is RCUS or OLMA more profitable?

Which has better earnings & valuation, RCUS or OLMA?

Does the media refer more to RCUS or OLMA?

Do analysts recommend RCUS or OLMA?

Which has more volatility and risk, RCUS or OLMA?

Summary

How does Olema Pharmaceuticals compare to Dyne Therapeutics?

Is DYN or OLMA more profitable?

Do analysts prefer DYN or OLMA?

Does the media refer more to DYN or OLMA?

Which has higher valuation & earnings, DYN or OLMA?

Which has more risk & volatility, DYN or OLMA?

Do institutionals and insiders have more ownership in DYN or OLMA?

Summary

How does Olema Pharmaceuticals compare to GRAIL?

Which has more risk & volatility, OLMA or GRAL?

Does the media prefer OLMA or GRAL?

Do institutionals & insiders believe in OLMA or GRAL?

Do analysts rate OLMA or GRAL?

Which has stronger valuation and earnings, OLMA or GRAL?

Is OLMA or GRAL more profitable?

Summary

How does Olema Pharmaceuticals compare to Denali Therapeutics?

Do analysts prefer DNLI or OLMA?

Do institutionals and insiders hold more shares of DNLI or OLMA?

Does the media favor DNLI or OLMA?

Is DNLI or OLMA more profitable?

Which has preferable valuation & earnings, DNLI or OLMA?

Which has more risk & volatility, DNLI or OLMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OLMA vs. The Competition

Olema Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools